

## **Genetic and Biochemical Evidence that Haploinsufficiency of the *Nf1* Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates In Vivo**

By David A. Ingram,<sup>\*||</sup> Feng-Chun Yang,<sup>\*||¶</sup> Jeffrey B. Travers,<sup>§||</sup>  
Mary Jo Wenning,<sup>\*||</sup> Kelly Hiatt,<sup>\*‡||</sup> Sheryl New,<sup>\*||</sup> Antoinette Hood,<sup>§</sup>  
Kevin Shannon,<sup>\*\*</sup> David A. Williams,<sup>\*||¶</sup> and D. Wade Clapp<sup>\*‡||</sup>

---

From the <sup>\*</sup>Department of Pediatrics, the <sup>‡</sup>Department of Microbiology and Immunology, the <sup>§</sup>Department of Dermatology, the <sup>||</sup>Herman B. Wells Center for Pediatric Research, the <sup>¶</sup>Howard Hughes Medical Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202; and the <sup>\*\*</sup>Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143

### **Abstract**

Neurofibromatosis type 1 (NF1) is a common autosomal-dominant disorder characterized by cutaneous neurofibromas infiltrated with large numbers of mast cells, melanocyte hyperplasia, and a predisposition to develop malignant neoplasms. *NF1* encodes a GTPase activating protein (GAP) for Ras. Consistent with Knudson's "two hit" model of tumor suppressor genes, leukemias and malignant solid tumors in NF1 patients frequently demonstrate somatic loss of the normal *NF1* allele. However, the phenotypic and biochemical consequences of heterozygous inactivation of *Nf1* are largely unknown. Recently neurofibromin, the protein encoded by *NF1*, was shown to negatively regulate Ras activity in *Nf1*<sup>-/-</sup> murine myeloid hematopoietic cells in vitro through the c-kit receptor tyrosine kinase (*dominant white spotting*, *W*). Since the *W* and *Nf1* locus appear to function along a common developmental pathway, we generated mice with mutations at both loci to examine potential interactions in vivo. Here, we show that haploinsufficiency at *Nf1* perturbs cell fates in mast cells in vivo, and partially rescues coat color and mast cell defects in *W*<sup>41</sup> mice. Haploinsufficiency at *Nf1* also increased mast cell proliferation, survival, and colony formation in response to Steel factor, the ligand for c-kit. Furthermore, haploinsufficiency was associated with enhanced Ras-mitogen-activated protein kinase activity, a major downstream effector of Ras, via wild-type and mutant (*W*<sup>41</sup>) c-kit receptors. These observations identify a novel interaction between c-kit and neurofibromin in vivo, and offer experimental evidence that haploinsufficiency of *Nf1* alters both cellular and biochemical phenotypes in two cell lineages that are affected in individuals with NF1. Collectively, these data support the emerging concept that heterozygous inactivation of tumor suppressor genes may have profound biological effects in multiple cell types.

Key words: c-kit • mast cell • heterozygous • neurofibromatosis • tumor suppressor

### **Introduction**

Neurofibromin, the protein encoded by neurofibromatosis type 1 (NF1), negatively regulates Ras output by accelerating the conversion of Ras-GTP to Ras-GDP (1, 2). The murine c-kit receptor (3) and its ligand, Steel factor (4, 5), are components of a signaling pathway that is essential for murine hematopoiesis, melanogenesis, and gametogenesis.

These proteins are encoded by the *dominant white spotting* (*W*) and *Steel* (*Sf*) loci, respectively, and ligand binding to c-kit activates Ras in myeloid lineage cells (for a review, see reference 6). Children with NF1 are at a markedly increased risk of developing juvenile myelomonocytic leukemia (JMML [7]). Genetic and biochemical analyses of these leukemias strongly support the hypothesis that *NF1* functions as a tumor suppressor gene in immature myeloid cells by negatively regulating Ras output. Similarly, ~10% of heterozygous *Nf1*<sup>+/-</sup> mice spontaneously develop a JMML-like myeloproliferative disorder (MPD) during the

---

Address correspondence to D. Wade Clapp, Indiana University School of Medicine, Cancer Research Institute, 1044 W. Walnut St., Rm. 421, Indianapolis, IN 46202. Phone: 317-274-4719; Fax: 317-274-8679; E-mail: dclapp@iupui.edu

second year of life with loss of the wild-type *Nf1* allele (8). In contrast to patients with NF1, *Nf1*<sup>+/-</sup> mice neither manifest pigmentary abnormalities nor develop neurofibromas (8). Although homozygous *Nf1* knockout mice (*Nf1*<sup>-/-</sup>) die in utero around embryonic day (E)13.5 from complex cardiovascular defects (8, 9), adoptive transfer of E13.5 *Nf1*<sup>-/-</sup> fetal liver hematopoietic stem cells into irradiated syngeneic recipients consistently induces the JMML-MPD (10). Interestingly, we have shown recently that murine *Nf1*<sup>-/-</sup> fetal liver cells form excessive numbers of myeloid progenitor colonies in methylcellulose cultures containing low concentrations of Steel factor. Mitogen-activated protein (MAP) kinase, a downstream target of Ras-GTP, is activated in unstimulated *Nf1*<sup>-/-</sup> myeloid lineage cells, and this kinase is hyperactivated in response to several hematopoietic growth factors, including GM-CSF and Steel factor (11). This observation and the involvement of myeloid, mast cell, and melanocyte lineages in some of the pathological complications of NF1 led us to generate mice with mutations at both *W* and *Nf1* to examine potential genetic and biochemical interactions in vivo and in vitro.

## Materials and Methods

**Animals.** *Nf1*<sup>+/-</sup> mice were obtained from Dr. Tyler Jacks at the Massachusetts Institute of Technology (Cambridge, MA) in a C57BL/6.129 background, and were backcrossed for 13 generations into the C57BL/6 strain. C57BL/6<sup>+/+</sup>; *W*<sup>41</sup>/*W*<sup>41</sup> mice were obtained from the Jackson Laboratory. These studies were conducted with a protocol approved by the Indiana University Laboratory Animal Research Center. The *Nf1* allele was genotyped as described previously (11, 12). The *W*<sup>41</sup> genotyping was inferred from the characteristic mottled, white coat color in *W*<sup>41</sup>/*W*<sup>41</sup> mice, and a white abdominal spot on *W*<sup>41</sup>/<sup>+</sup> mice. Multiple F0 founders were used to generate the F2 progeny used in these experiments. The crosses used to generate the four *Nf1* and *W* genotypes used in these experiments are outlined below:

F0: *Nf1*<sup>+/-</sup>; <sup>+/+</sup> × <sup>+/+</sup>; *W*<sup>41</sup>/*W*<sup>41</sup>  
 F1: *Nf1*<sup>+/-</sup>; *W*<sup>41</sup>/<sup>+</sup> × <sup>+/+</sup>; *W*<sup>41</sup>/<sup>+</sup>  
 F2: *Nf1*<sup>+/-</sup>; *W*<sup>41</sup>/*W*<sup>41</sup>, <sup>+/+</sup>; *W*<sup>41</sup>/*W*<sup>41</sup>,  
*Nf1*<sup>+/-</sup>; <sup>+/+</sup>, <sup>+/+</sup>; <sup>+/+</sup>.

**Analysis of Cutaneous Mast Cells.** 1-cm sections of ears and dorsal skin were removed, fixed in buffered formalin, and processed in paraffin-embedded sections. Specimens were stained with hematoxylin-eosin to assess routine histology, and with Giemsa to identify mast cells. Some specimens were stained with Fontana-Masson to differentiate melanin-containing cells from mast cells. Cutaneous mast cells (Giemsa-positive, Fontana-Masson-negative) were quantitated in a blinded fashion by counting the distal 5 mm of ears or dorsal skin.

**Peritoneal Lavages and Mast Cell Colony Assays.** Peritoneal cells from 8-wk-old mice were collected as described previously (13). 10-ml peritoneal lavages were then concentrated by centrifugation and stained with toluidine blue to quantify total number of mast cells per 10 ml lavage. To examine the proliferation of peritoneal cells for mast cell progenitors, mast cell colony assays were done in triplicate. In brief, 1 ml of culture mix containing 1 × 10<sup>4</sup> peritoneal cells, α-MEM, 1.2% methylcellulose (Terry Fox Laboratory), 30% fetal bovine serum (HyClone Laboratories), 1%

deionized fraction V BSA (Sigma Chemical Co.), 10<sup>-4</sup> M mercaptoethanol (Sigma Chemical Co.), 10 ng/ml of recombinant murine IL-3, and 100 ng/ml of recombinant murine Steel factor (PeproTech) was plated in each 35-mm suspension culture dish (Nalge Nunc International), then incubated at 37°C in a humidified atmosphere flush with 5% CO<sub>2</sub> in air. Colonies were determined on day 14 of incubation by in situ observation using an inverted microscope. To assess the accuracy of in situ identification of the colonies, individual colonies were taken with an Eppendorf micropipette under direct microscope visualization, spread on glass slides using cytocentrifuge, and stained with May-Grunwald-Giemsa stain and Alcian blue/safranin stain for mast cells.

**Bone Marrow Mast Cell Culture and Survival Assay.** Six lines from each of the four genotypes were generated and used for cell survival and proliferation assays. Bone marrow mast cells (BMMCs) were cultured as described, with minor modifications (14), and homogeneity of BMMCs was determined by Giemsa staining. Aliquots of cells were also stained with Alcian blue and safranin to confirm that they were mast cells. Furthermore, FACS<sup>®</sup> analysis revealed similar forward and side light scatter characteristics and the same percentage of c-kit<sup>+</sup> cells in BMMCs of all four genotypes (data not shown). The mast cell survival assay was done as follows: BMMCs from each genotype were deprived of growth factors for 24 h, and 3 × 10<sup>5</sup> cells were plated in 24-well dishes in serum-free RPMI containing 1% glutamine and 100 ng/ml of recombinant murine Steel factor in a total volume of 1 ml. The number of surviving cells was determined by trypan blue exclusion at 48 h of culture in a 37°C, 5% CO<sub>2</sub>, humidified incubator.

**Proliferation Assay.** Proliferation assays were performed as described previously (14). BMMCs were deprived of growth factors for 24 h, and 2 × 10<sup>5</sup> cells were plated in triplicate in 24-well dishes in 1 ml RPMI containing 1% glutamine, 10% fetal bovine serum, and 100 ng/ml recombinant murine Steel factor or no growth factors as indicated in a 37°C, 5% CO<sub>2</sub>, humidified incubator. After 1 and 3 d, viable cells were counted using a hemocytometer. Cell viability was determined by a trypan blue exclusion assay.

**Analysis of p42 MAP Kinase Activation.** Activation of p42 MAP kinase was determined by depriving cells of growth factors for 24 h and stimulating them with 10 ng/ml of recombinant murine Steel factor for various amounts of time. Cells were collected and washed twice with cold PBS plus 1 mM sodium orthovanadate, and then lysed in nonionic lysis buffer as described previously (15). The protein lysates were equalized for total protein concentration using a BCA assay (Pierce Chemical Co.), and equal loading of MAP kinases in these assays was confirmed by Western blot. p42 MAP kinase immunoprecipitations were carried out with an anti-extracellular signal-regulatory kinase (ERK)-2 (C-14) antibody (Santa Cruz Biotechnology). The p42 MAP kinase immune complex assay was performed as described, except that Elk-1 fusion protein (New England Biolabs) was used instead of myelin basic protein. The kinase reactions were resolved on 10% SDS-PAGE gels. Gels were dried and subjected to autoradiography. Densitometry of individual bands was conducted using NIH Image software.

## Results


**Haploinsufficiency at *Nf1* Partially Restores the Coat Color Deficiency in *W*<sup>41</sup> Mice.** *W* mice display varying degrees of sterility, mast cell hypoplasia, anemia, and coat color deficiency correlating with the residual kinase activity of the mutant receptor (16, 17). Mice homozygous for a point mutation in the

cytoplasmic domain of the c-kit receptor ( $W^{41}$ ) have partial inactivation of the c-kit receptor tyrosine kinase, resulting in an abnormal mottled, white coat color (17). We crossed  $W^{41}$  and  $Nf1$  mice and found that animals heterozygous at  $Nf1$  and homozygous for the  $W^{41}$  mutation ( $Nf1+/-;W^{41}/W^{41}$ ) displayed a 60–70% restoration of coat color (Fig. 1 A). This finding was consistent in >150 F2 progeny carrying mutations at both loci. Thus, haploinsufficiency at  $Nf1$  partially corrects the aberrant pigmentation pattern of  $W^{41}/W^{41}$  mice.

**Haploinsufficiency at  $Nf1$  Increases Peritoneal and Cutaneous Mast Cell Numbers in Wild-Type and  $W^{41}$  Mice.** Mice homozygous for different mutant  $W$  alleles have reduced numbers of peritoneal and cutaneous mast cells (17, 18). To investigate whether heterozygous inactivation of  $Nf1$  could modulate the deficiency of this lineage, we compared numbers of peritoneal mast cells harvested from  $Nf1+/-;W^{41}/W^{41}$  animals to those taken from singly mutant mice ( $+/+;W^{41}/W^{41}$ ). We also compared peritoneal mast cell numbers in  $Nf1+/-;+/+$  and wild-type mice. Cells isolated by peritoneal lavage were stained with toluidine blue to identify mast cells. Representative cytopspins from individual mice from each of the four  $Nf1$  and  $W$  genotypes are shown in Fig. 1 B. Peritoneal mast cell numbers in  $Nf1+/-;W^{41}/W^{41}$  mice were 40-fold higher than in  $+/+;$

$W^{41}/W^{41}$  littermates (Table I). Importantly, in addition to restoring peritoneal mast cell numbers to ~10% of wild-type levels in  $W^{41}/W^{41}$  mice, heterozygous inactivation of  $Nf1$  significantly increased mast cell numbers in animals that were wild-type at the  $W$  locus (Table I). We performed similar experiments to determine if haploinsufficiency at  $Nf1$  increased numbers of cutaneous mast cells in the mutant  $W^{41}/W^{41}$  and wild-type backgrounds. Giemsa-stained ear biopsies from mice of the four  $W$  and  $Nf1$  genotypes are shown in Fig. 1 C. Ear biopsies from  $Nf1+/-;W^{41}/W^{41}$  mice showed a twofold increase in numbers of cutaneous mast cells compared with  $+/+;W^{41}/W^{41}$  mice (Table I).  $Nf1+/-;+/+$  mice also had a modest, though statistically insignificant, increase in cutaneous mast cell numbers compared with wild-type mice (Table I). Giemsa-stained biopsies obtained from a second site (dorsal skin) revealed similar differences in cutaneous mast cell numbers between the genotypes (data not shown). The increased numbers of peritoneal and cutaneous mast cells in  $Nf1+/-$  mice provide additional evidence that haploinsufficiency augments signaling through the c-kit receptor in vivo.

**Haploinsufficiency at  $Nf1$  Increases Colony Formation, Proliferation, and Survival of Mast Cells in Response to Steel Factor in  $W^{41}$  and Wild-Type Mice.** IL-3 and Steel factor support



**Figure 1.** Effect of haploinsufficiency of  $Nf1$  on coat color and total numbers of cutaneous and peritoneal mast cells. (A) Coat color pattern of a representative mouse from each of the following genotypes:  $+/+;+/+$ ,  $Nf1+/-;+/+$ ,  $+/+;W^{41}/W^{41}$ , and  $Nf1+/-;W^{41}/W^{41}$ . Haploinsufficiency at  $Nf1$  partially corrects the coat color deficiency in mice homozygous for the  $W^{41}$  allele in a C57BL/6 genetic background. (B) Representative cytopspins from peritoneal lavages stained for mast cells from individual mice of the four  $Nf1$  and  $W$  genotypes. Peritoneal cells were stained with toluidine blue to quantify the total number of mast cells per peritoneal lavage. A higher magnification of a representative mast cell is shown in the inset of the wild-type mouse (original magnification:  $\times 200$ ). Bar (inset) 10  $\mu\text{m}$ . Bar (far right) 30  $\mu\text{m}$ . (C) Representative ear biopsies stained for cutaneous mast cells from individual mice of the four  $Nf1$  and  $W$  genotypes. Specimens were stained with hematoxylin-eosin to assess routine histology, and with Giemsa to identify mast cells. Ear biopsies were stained with Fontana-Masson to differentiate melanin-containing cells from mast cells. Cutaneous mast cells (Giemsa-positive, Fontana-Masson-negative) were quantitated in a blinded fashion by counting the distal 5 mm of ears. Black arrows indicate Giemsa-positive mast cells, and open arrows indicate Fontana-Masson melanin-containing cells. Bar, 35  $\mu\text{m}$ .

**Table I.** Effects of *W* and *Nfl* Genotypes on Mast Cell Numbers and Mast Cell Colony Growth

	Genotype			
	<i>+/+</i> <i>+/+</i>	<i>Nfl</i> <i>+/-</i> <i>+/+</i>	<i>+/+</i> <i>W<sup>41</sup>/W<sup>41</sup></i>	<i>Nfl</i> <i>+/-</i> <i>W<sup>41</sup>/W<sup>41</sup></i>
No. of peritoneal mast cells ( $\times 10^2$ )	780 $\pm$ 10	1,000 $\pm$ 14*	2 $\pm$ 1	81 $\pm$ 17*
No. of cutaneous mast cells (mm <sup>2</sup> )	25.6 $\pm$ 7	31 $\pm$ 2	6 $\pm$ 1	14 $\pm$ 2*
No. of mast cell colonies ( $\times 10^2$ )	79 $\pm$ 6	117 $\pm$ 9*	0	8 $\pm$ 0.8*


Nos. of peritoneal and cutaneous mast cells were quantitated from peritoneal lavages and ear biopsies. Results represent mean numbers of mast cells  $\pm$  SEM from six animals in each genotype. Peritoneal cells were cultured for the growth of mast cell colonies as described (reference 13), and results represent the mean number of mast cell colonies  $\pm$  SEM of six independent experiments.

\**P* < 0.05 for comparison of *Nfl**+/+* and *Nfl**+/-* in both *W<sup>41</sup>/W<sup>41</sup>* and wild-type genetic backgrounds by Student's paired *t* test.

clonal mast cell colony formation from bone marrow and mature mast cells in vitro. To further characterize interactions between *W* and *Nfl*, we assessed the ability of peritoneal cells isolated from mice of all four genotypes to form mast cell colonies in methylcellulose cultures (13). No mast cell progenitor colonies formed in cultures of *+/+; W<sup>41</sup>/W<sup>41</sup>* peritoneal cells (Table I). In contrast, cells from *Nfl**+/-; W<sup>41</sup>/W<sup>41</sup>* mice formed significant numbers of mast cell colonies in this assay. Heterozygous inactivation of *Nfl* also significantly enhanced the growth of mast cell colonies in mice that were wild-type at the *W* locus (Table I).

C-kit receptor activation in BMMCs mediates diverse biological responses, including proliferation. To assess whether haploinsufficiency at *Nfl* augments the proliferative re-

sponses of a homogeneous population of mast cells to Steel factor, the growth kinetics of *Nfl**+/-* BMMCs were compared with *Nfl**+/+* cells in mice with a normal or mutant (*W<sup>41</sup>*) c-kit receptor. BMMCs from mice of each genotype were cultured in 10% FCS without added growth factors for 24 h before the addition of Steel factor. Cell numbers were determined at the time Steel factor was added (day 0) and after 24 and 72 h in culture. *Nfl**+/-* cells of both *W* genotypes showed greater proliferative responses to Steel factor after 24 and 72 h in culture than the corresponding *Nfl**+/+* populations (Fig. 2 A). Using the same experimental design, thymidine incorporation assays gave similar results (data not shown). Thus, haploinsufficiency at *Nfl* is associated with an increased proliferative response of wild-



**Figure 2.** Effect of haploinsufficiency of *Nfl* and *W* on the survival and proliferation of BMMCs in response to Steel factor. (A) Proliferation of BMMCs from mice of the four *Nfl* and *W* genotypes in response to recombinant murine Steel factor. After deprivation of growth factors for 24 h,  $2 \times 10^5$  cells/ml were plated in triplicate in 24-well dishes in RPMI containing 1% glutamine, 10% fetal bovine serum, and 100 ng/ml of Steel factor in a total volume of 1 ml as described previously (reference 29). After 1 and 3 d, viable cells were counted using a hemocytometer and expressed as a percentage of input cells. \**P* < 0.05, *Nfl**+/-; W<sup>41</sup>/W<sup>41</sup>* vs. *+/+; W<sup>41</sup>/W<sup>41</sup>* and *Nfl**+/-; +/+* vs. *+/+; +/+* cells by Student's paired *t* test. (B) Percent survival of BMMCs of the four *Nfl* and *W* genotypes. After deprivation of growth factors for 24 h,  $3 \times 10^5$  cells of each genotype were plated in RPMI containing 1% BSA and 100 ng/ml of recombinant murine Steel factor. The number of surviving cells was determined by trypan blue exclusion and expressed as a percentage of input cells. \**P* < 0.05, *Nfl**+/-; W<sup>41</sup>/W<sup>41</sup>* vs. *+/+; W<sup>41</sup>/W<sup>41</sup>* and *Nfl**+/-; +/+* vs. *+/+; +/+* cells by Student's paired *t* test.


type and  $W^{41}/W^{41}$  BMMCs in liquid cultures containing 10% FCS and exogenous Steel factor.

Steel factor acts as both a mitogen and a survival factor for mast cells (5, 17, 19). Mast cells derived from different lines of  $W$  mutant mice display reduced or no survival when cultured in the presence of Steel factor alone, which correlates with residual receptor tyrosine kinase activity (17, 19). Therefore, we examined the effect of heterozygous inactivation of  $Nf1$  on the survival of BMMCs isolated from wild-type and  $W^{41}/W^{41}$  mice (Fig. 2 B).  $Nf1+/-$  BMMCs of both  $W$  genotypes demonstrated increased survival compared with  $Nf1+/+$  cells after 48 h of culture in serum-free media in response to exogenous Steel factor. Since this assay has been shown to correlate with c-kit receptor tyrosine kinase activity (19), we quantitated surface expression of c-kit on the four  $W$  and  $Nf1$  genotypes by fluorescence cytometry to ensure that these differences in cell survival were not explained by variable levels of receptor expression. No differences were observed (data not shown).

**Haploinsufficiency at  $Nf1$  Increases MAP Kinase Activity in Response to Steel Factor in Wild-Type and  $W^{41}$  Mice.** The data presented above provide evidence that haploinsufficiency of  $Nf1$  augments the proliferation and survival of wild-type and  $W^{41}/W^{41}$  mast cells in vitro and in vivo. Partial restoration of normal coat color in  $Nf1+/-;W^{41}/W^{41}$  mice indicates that this effect is not restricted to hematopoietic cells, but also includes melanocytes. The Ras-MAP kinase pathway is an important downstream target of c-kit receptor activation, and neurofibromin negatively regulates Ras signaling by functioning as a GTPase activating protein (GAP) for Ras (20, 21). The phenotypic data presented above suggest a model whereby heterozygous inactivation of  $Nf1$  enhances c-kit-induced Ras output by reducing neurofibromin levels (and GAP activity for Ras) in susceptible cell lineages. To test this hypothesis, we stimulated primary BMMCs with Steel factor, and measured p42 MAP kinase. MAP kinase protein levels were similar in BMMCs of all genotype combinations (data not shown).  $Nf1+/-;W^{41}/W^{41}$  BMMCs demonstrated a fivefold greater increase in MAP kinase activity from baseline 5 min after the addition of Steel factor relative to  $+/+;W^{41}/W^{41}$  BMMCs (Fig. 3). Indeed, haploinsufficiency of  $Nf1$  restored the ability of the mutant  $W^{41}$  c-kit receptor to activate MAP kinase to wild-type levels at the 5-min time point (Fig. 3). Similarly,  $Nf1+/-;+/+$  BMMCs had a twofold greater increase in MAP kinase activity from baseline compared with wild-type mast cells that was sustained at both tested time points (Fig. 3). These biochemical data indicate that the phenotypic effects in  $Nf1+/-$  mast cells correlate with enhanced signaling through a major downstream effector of Ras-GTP.

## Discussion

In these experiments, we present genetic, cellular, and biochemical data demonstrating that neurofibromin negatively regulates signaling through the c-kit receptor tyrosine kinase in a haploinsufficient state. Dermal cafe au lait



**Figure 3.** Analysis of p42 MAP kinase activity from BMMCs stimulated with Steel factor in the four  $Nf1$  and  $W$  genotypes. Activation of p42 MAP kinase was determined by depriving cells of growth factors for 24 h, followed by stimulation with 10 ng/ml of Steel factor for 5 and 15 min. Autoradiography and quantitative densitometry of the phosphorylation of Elk-1 fusion protein by MAP kinase from lysates obtained from Steel factor-stimulated BMMCs are shown. Data represent one of three independent experiments. Similar results were obtained in two other experiments.

macules, learning disabilities, and the development of multiple cutaneous neurofibromas are major nonmalignant pathologic complications of NF1. Although the finding of constitutional heterozygosity (LOH) in some neurofibromas supports the “two hit” tumor suppressor model (22, 23), many of these lesions retain the normal  $NF1$  allele. Other features of neurofibroma biology, including the very large numbers of lesions found in some patients, their self-limited growth, and the low propensity of these tumors to undergo malignant degeneration are also consistent with a possible dosage effect on cell growth. Neurofibromas are infiltrated with mast cells that have been hypothesized to promote growth by releasing mediators that act locally upon Schwann cells, endothelial cells, and fibroblasts (24). Treatment with mast cell stabilizers is associated with a reduction in pruritus in some patients with NF1, and represents the only known medical treatment that alters the growth of neurofibromas (24). Given the importance of Steel factor in regulating multiple mast cell functions, our data showing that haploinsufficiency at  $Nf1$  alters mast cell numbers, survival, and Ras signaling in wild-type and  $W^{41}/W^{41}$  mice in response to Steel factor implicate deregulated mast cell function as potentially important in neurofibroma formation.

In a recent study, Hemesath et al. (25) implicated the Microphthalmia (Mi) transcription factor as a direct target of MAP kinase activation in response to c-kit. The observation that haploinsufficiency at  $Nf1$  effects a 60–70% rescue of the pigmented defect seen in  $W^{41}/W^{41}$  mice further supports the central role of this pathway in melanocyte development, and is consistent with the marked enhancement of

Steel factor-induced MAP kinase activation that we observed in *Nf1*<sup>+/-</sup> mast cells. Although the molecular basis of cutaneous melanocyte hyperplasia in NF1 is poorly understood, our data suggest that melanocytes from *Nf1*<sup>+/-</sup> mice could offer an attractive system for discerning the role of *Nf1* in examining the c-kit-MAP kinase-Mi pathway.

The relative contributions of homozygous *NF1* inactivation and of haploinsufficiency to the pathologic complications of NF1 remain incompletely understood. Genetic analysis of malignant peripheral nerve sheath tumors (MPNSTs), pheochromocytomas, and myeloid leukemias from individuals with NF1 and *Nf1*<sup>+/-</sup> mice have demonstrated frequent somatic loss of the normal allele (8, 26–29). Homozygous inactivation of *NF1* in a human MPNST, in several leukemias, and in a variety of murine tumors provides formal proof that the gene functions as a tumor suppressor in a subset of cancers (8, 30). Although these data confirm that tumorigenesis follows the Knudson paradigm (31) in some patients and in *Nf1* mice, many tumors do not show loss of LOH, and it is uncertain if inactivation of both alleles is a prerequisite for tumor formation. In a recent study of heterozygous *p53* knockout mice, some tumors retained a functional *p53* allele (32). Tumor formation in *p27* knockout mice is also associated with haploinsufficiency (33). The phenotypes that we have detected in *Nf1*<sup>+/-</sup> cells of two lineages suggest that haploinsufficiency may confer a growth advantage that could contribute to tumorigenesis by pathways that do not require inactivation of the normal allele. Full genetic and biochemical characterization of tumors from patients with NF1 and from *Nf1*<sup>+/-</sup> mice that retain heterozygosity is required to address this possibility. Finally, the finding that haploinsufficiency at *Nf1* has dramatic phenotypic consequences in two cell lineages that are affected in NF1 patients has important therapeutic implications. In particular, if diseased cells retain a functional *NF1* allele, increasing neurofibromin-specific GAP activity is an attractive strategy for preventing or treating the complications of NF1.

We are grateful to Dr. Tyler Jacks for generously providing *Nf1* mice and for helpful discussions. We also thank our colleagues Drs. Hal Broxmeyer, Mervin Yoder, and Mary Dinauer for reading the manuscript.

This work was supported by a National Institutes of Health grant through the Pediatric Scientist Development Program to D.A. Ingram, by American Cancer Society grant DB80030 to K. Shannon and D.W. Clapp, by National Institutes of Health grant RO1CA73614 to K. Shannon, and by March of Dimes Birth Defects Foundation grant 6FY98-0219 and National Institutes of Health grant R29 (CA74177-01) to D.W. Clapp.

Submitted: 1 June 1999  
 Revised: 12 October 1999  
 Accepted: 18 October 1999

## References

1. Viskochil, D., A.M. Buchberg, G. Xu, R.M. Cawthon, J. Stevens, R.K. Wolff, M. Culver, J.C. Carey, N.G. Copeland, and N.A. Jenkins. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. *Cell*. 62:187–192.
2. Wallace, M.R., D.A. Marchuk, L.B. Andersen, R. Letcher, H.M. Odeh, A.M. Saulino, J.W. Fountain, A. Brereton, J. Nicholson, and A.L. Mitchell. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. *Science*. 249:181–186.
3. Chabot, B., D.A. Stephenson, V.M. Chapman, P. Besmer, and A. Bernstein. 1988. The proto-oncogene *c-kit* encoding a transmembrane tyrosine kinase receptor maps to the mouse *W* locus. *Nature*. 335:88–89.
4. Copeland, N.G., D.J. Gilbert, B.C. Cho, P.J. Donovan, N.A. Jenkins, D. Cosman, D. Anderson, S.D. Lyman, and D.E. Williams. 1990. Mast cell growth factor maps near the *steel* locus on mouse chromosome 10 and is deleted in a number of steel alleles. *Cell*. 63:175–183.
5. Zsebo, K.M., D.A. Williams, E.N. Geissler, V.C. Broudy, F.H. Martin, H.L. Atkins, R.-Y. Hsu, N.C. Birkett, K.H. Okino, D.C. Murdock, et al. 1990. Stem cell factor is encoded at the *Sl* locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. *Cell*. 63:213–224.
6. Broudy, V.C. 1997. Stem cell factor and hematopoiesis. *Blood*. 90:1345–1364.
7. Side, L., B. Taylor, M. Cayouette, E. Conner, P. Thompson, M. Luce, and K. Shannon. 1997. Homozygous inactivation of the *NF1* gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. *N. Engl. J. Med.* 336:1713–1720.
8. Jacks, T., T.S. Shih, E.M. Schmitt, R.T. Bronson, A. Bernards, and R.A. Weinberg. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in *Nf1*. *Nat. Genet.* 7:353–361.
9. Brannan, C.I., A.S. Perkins, K.S. Vogel, N. Ratner, M.L. Nordlund, S.W. Reid, A.M. Buchberg, N.A. Jenkins, L.F. Parada, and N.G. Copeland. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. *Genes Dev.* 8:1019–1029.
10. Largaespada, D.A., C.I. Brannan, N.A. Jenkins, and N.G. Copeland. 1996. *Nf1* deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. *Nat. Genet.* 12:137–143.
11. Zhang, Y.Y., T.A. Vik, J.W. Ryder, E.F. Srouf, T. Jacks, K. Shannon, and D.W. Clapp. 1998. *Nf1* regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. *J. Exp. Med.* 187:1893–1902.
12. Bollag, G., D.W. Clapp, S. Shih, F. Adler, Y.Y. Zhang, P. Thompson, B.J. Lange, M.H. Freedman, F. McCormick, T. Jacks, and K. Shannon. 1996. Loss of *NF1* results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. *Nat. Genet.* 12:144–148.
13. Nakahata, T., and M. Ogawa. 1982. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. *Proc. Natl. Acad. Sci. USA.* 79:3843–3847.
14. Serve, H., N.S. Yee, G. Stella, L. Sepp-Lorenzino, J.C. Tan, and P. Besmer. 1995. Differential roles of P13-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. *EMBO (Eur. Mol. Biol. Organ.) J.* 14:473–483.
15. Bollag, G., F. Adler, N. elMasry, P.C. McCabe, E. Conner, Jr., P. Thompson, F. McCormick, and K. Shannon. 1996.

- Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. *J. Biol. Chem.* 271:32491–32494.
16. Nocka, K., J.C. Tan, E. Chiu, T.Y. Chu, P. Ray, P. Traktman, and P. Besmer. 1990. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus:  $W^{37}$ ,  $W^v$ ,  $W^{41}$  and  $W$ . *EMBO (Eur. Mol. Biol. Organ.) J.* 9:1805–1813.
  17. Blouin, R., and A. Bernstein. 1993. The white spotting and steel hereditary anemias of the mouse. In *Clinical Disorders and Experimental Models of Erythropoietic Failure*. S. Feig and M. Freedman, editors. CRC Press, Boca Raton, FL. 1257–1273.
  18. Tsujimura, T., U. Koshimizu, H. Katoh, K. Isozaki, Y. Kanakura, T. Tono, S. Adachi, T. Kasugai, H. Tei, Y. Nishimune, et al. 1993. Mast cell number in the skin of heterozygotes reflects the molecular nature of c-kit mutation. *Blood.* 81:2530–2538.
  19. Paulson, R.F., S. Vesely, K.A. Siminovitich, and A. Bernstein. 1996. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. *Nat. Genet.* 13:309–315.
  20. Xu, G.F., P. O'Connell, D. Viskochil, R. Cawthon, M. Robertson, M. Culver, D. Dunn, J. Stevens, R. Gesteland, R. White, and R. Weiss. 1990. The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell.* 62:599–608.
  21. Skuse, G.R., B.A. Kosciulek, and P.T. Rowley. 1989. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. *Genes Chromosomes Cancer.* 1:36–41.
  22. Stark, M., G. Assum, and W. Krone. 1995. Single-cell PCR performed with neurofibroma Schwann cells reveals the presence of both alleles of the neurofibromatosis type 1 (NF1) gene. *Hum. Genet.* 96:619–623.
  23. Sawada, S., S. Florell, S.M. Purandare, M. Ota, K. Stephens, and D. Viskochil. 1996. Identification of NF1 mutations in both alleles of dermal neurofibroma. *Nat. Genet.* 14:110–112.
  24. Riccardi, V.M. 1992. Neurofibromatosis: Phenotype, Natural History and Pathogenesis. 2nd ed. Johns Hopkins University Press, Baltimore. 498 pp.
  25. Hemesath, T.J., E.R. Price, C. Takemoto, T. Badalian, and D.E. Fisher. 1998. MAP kinase links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. *Nature.* 391:298–301.
  26. Glover, T.W., C.K. Stein, E. Legius, L.B. Andersen, A. Brereton, and S. Johnson. 1991. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. *Genes Chromosomes Cancer.* 3:62–70.
  27. Menon, A.G., K.M. Anderson, V.M. Riccardi, R.Y. Chung, J.M. Whaley, D.W. Yandell, G.E. Farmer, R.N. Freiman, J.K. Lee, F.P. Li, et al. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. *Proc. Natl. Acad. Sci. USA.* 87:5435–5439.
  28. Shannon, K.M., P. O'Connell, G.A. Martin, D. Paderanga, K. Olson, P. Dinndorf, and F. McCormick. 1994. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. *N. Engl. J. Med.* 330:597–601.
  29. Xu, W., L.M. Mulligan, M.A. Ponder, L. Liu, B.A. Smith, C.G. Mathew, and B.A. Ponder. 1992. Loss of alleles in pheochromocytomas from patients with type 1 neurofibromatosis. *Genes Chromosomes Cancer.* 4:337–342.
  30. Legius, E., D.A. Marchuk, F.S. Collins, and T.W. Glover. 1993. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. *Nat. Genet.* 3:122–126.
  31. Knudson, A.J. 1985. Hereditary cancer, oncogenes, and anti-oncogenes. *Cancer Res.* 45:1437–1443.
  32. Venkatachalam, S., Y.-P. Shi, S.N. Jones, H. Vogel, A. Bradley, D. Pinkel, and L.A. Donehower. 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. *EMBO (Eur. Mol. Biol. Organ.) J.* 17:4657–4667.
  33. Fero, M.L., E. Randel, K.E. Gurley, J.M. Roberts, and C.J. Kemp. 1998. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. *Nature.* 396:177–180.